When the "Scytale" of Alcohol Runs in a Family and Alcohol Use Becomes a Transgenerational Issue: Case Report of a Father and Son Attending the Same Therapeutic Program.

Children whose parents are diagnosed with alcohol use problems are exposed to genetic and environmental risk factors and face a greater risk of developing mental health and behavioral problems and a higher risk of alcohol use. In this study, we present the case of a father and his son, both diagnosed with alcohol use disorder, who both attended, 12 years apart, the Inpatient Alcohol Treatment Program of the Alcohol Treatment Unit, in the Psychiatric Hospital of Attica, in Athens. The Alcohol Treatment Unit offers two inpatient treatment programs that have been operating since 1996 and are based on the principles of the Therapeutic Community.

The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy.

Malignancies are among the leading causes of mortality worldwide. Early detection and treatment are the primary targets of clinical and translational research, and may be facilitated by the recognition of novel diagnostic and prognostic biomarkers. Decoy receptor 3 (DcR3) is a soluble receptor of the tumor necrosis factor receptor superfamily of proteins (TNFRSF), which associates with its respective TNF-like ligands, Fas-L, LIGHT, and TL1A.

Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation.

Capecitabine is an oral 5-fluorouracil prodrug with antimetabolite activity commonly used in advanced colorectal and breast cancer. It presents with a generally good toxicity profile and most of the adverse events can be managed effectively. Enterocolitis is a rare, under-reported, but potentially fatal adverse event associated with capecitabine use.

Venous thromboembolism in COVID-19: A systematic review and meta-analysis.

Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous thromboembolism events (VTE). This study performed a systematic review in PubMed/EMBASE of studies reporting the prevalence of VTE in patients with COVID-19 who were totally screened/assessed for deep vein thrombosis (DVT) and/or for pulmonary embolism (PE). Among 47 candidate studies ( = 6459; 33 in Europe), 17 studies ( = 3973; weighted age 63.